{"clinical_study": {"@rank": "45", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 06, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04307693"}, "id_info": {"org_study_id": "S2020-0472-0001", "nct_id": "NCT04307693"}, "brief_title": "Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)", "official_title": "Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)", "sponsors": {"lead_sponsor": {"agency": "Asan Medical Center", "agency_class": "Other"}}, "source": "Asan Medical Center", "oversight_info": {"has_dmc": "No", "is_fda_regulated_drug": "No", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral\n      activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there\n      is no clinical studies on the reduction of viral load in patients with COVID-19. This study\n      investigate whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from\n      respiratory specimen in patients with mild COVID-19."}, "detailed_description": {"textblock": "This multicenter study is an open-labelled, randomized clinical trial for 1:1:1 ratio of\n      lopinavir/ritonavir, hydroxychloroquine, or control arm."}, "overall_status": "Recruiting", "start_date": {"@type": "Actual", "#text": "March 11, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "May 2020"}, "primary_completion_date": {"@type": "Anticipated", "#text": "May 2020"}, "phase": "Phase 2", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "intervention_model_description": "Multicenter, open labelled, randomized clinical trial", "primary_purpose": "Treatment", "masking": "None (Open Label)"}, "primary_outcome": {"measure": "Viral load", "time_frame": "hospital day 3, 5, 7, 10, 14, 18", "description": "Area under the curve (AUC) of Ct value or viral copies number per mL"}, "secondary_outcome": [{"measure": "Viral load change", "time_frame": "hospital day 3, 5, 7, 10, 14, 18", "description": "Viral load change (log10 viral load assessed by reverse transcription-PCR) during hospital day 3, 5, 7, 10, 14, 18)"}, {"measure": "Time to clinical improvement (TTCI)", "time_frame": "up to 28 days", "description": "Time to clinical improvement (TTCI) is defined as the time to normalization of fever, respiratory rate, and oxygen saturation, and alleviation of cough within at least 72 hours"}, {"measure": "Percentage of progression to supplemental oxygen requirement by day 7", "time_frame": "hospital day 7", "description": "Percentage of progression to supplemental oxygen requirement by day 7"}, {"measure": "Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7", "time_frame": "hospital day 7", "description": "Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7"}, {"measure": "Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission", "time_frame": "up to 28 days", "description": "Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission"}, {"measure": "Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7", "time_frame": "hospital day 7", "description": "Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7"}, {"measure": "adverse effects", "time_frame": "up to 28 days", "description": "Safety and tolerability, as assessed by adverse effects"}, {"measure": "Concentration of Lopinavir/ritonavir and hydroxychloroquine", "time_frame": "1, 2, 4, 5, 12 hours after taking intervention medicine", "description": "Concentration of Lopinavir/ritonavir and hydroxychloroquine"}], "number_of_arms": "3", "enrollment": {"@type": "Anticipated", "#text": "150"}, "condition": "COVID-19", "arm_group": [{"arm_group_label": "Lopinavir/ritonavir", "arm_group_type": "Experimental", "description": "Lopinavir/ritonavir 200mg/100mg 2 tablets by mouth, every 12 hours for 7-10 days"}, {"arm_group_label": "Hydroxychloroquine", "arm_group_type": "Active Comparator", "description": "Hydroxychloroquine 200mg 2 tablets by mouth, every 12 hours for 7-10 days"}, {"arm_group_label": "Control", "arm_group_type": "No Intervention", "description": "No lopinavir/ritonavir and hydroxychloroquine"}], "intervention": [{"intervention_type": "Drug", "intervention_name": "Lopinavir/ritonavir", "description": "Lopinavir / Ritonavir tablet", "arm_group_label": "Lopinavir/ritonavir", "other_name": "Kaletra"}, {"intervention_type": "Drug", "intervention_name": "Hydroxychloroquine sulfate", "description": "Hydroxychloroquine sulfate tablet", "arm_group_label": "Hydroxychloroquine", "other_name": "Oxiklorin"}], "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n          -  confirmed mild COVID-19 (NEWS scoring system 0-4)\n\n        Exclusion Criteria:\n\n          -  unable to take oral medication\n\n          -  pregnancy or breast feeding\n\n          -  immunocompromised patients\n\n          -  creatinine clearance (CCL) < 30 mL/min\n\n          -  aspartate transaminase (AST) or alanine transaminase (ALT) > 5 times Upper limit of\n             normal (ULN)"}, "gender": "All", "minimum_age": "16 Years", "maximum_age": "99 Years", "healthy_volunteers": "No"}, "location": {"facility": {"name": "Asan Medical Center, University of Ulsan College of Medicine", "address": {"city": "Seoul", "zip": "138-736", "country": "Korea, Republic of"}}, "status": "Recruiting", "contact": {"last_name": "Sung-Han Kim, MD.PhD", "phone": "82-2-3010-3114", "phone_ext": "3305", "email": "shkimmd@amc.seoul.kr"}, "investigator": {"last_name": "Sung-Han Kim, MD.PhD", "role": "Principal Investigator"}}, "location_countries": {"country": "Korea, Republic of"}, "verification_date": "March 2020", "study_first_submitted": "March 10, 2020", "study_first_submitted_qc": "March 12, 2020", "study_first_posted": {"@type": "Actual", "#text": "March 13, 2020"}, "last_update_submitted": "March 12, 2020", "last_update_submitted_qc": "March 12, 2020", "last_update_posted": {"@type": "Actual", "#text": "March 13, 2020"}, "responsible_party": {"responsible_party_type": "Principal Investigator", "investigator_affiliation": "Asan Medical Center", "investigator_full_name": "Sung-Han Kim", "investigator_title": "Professor"}, "condition_browse": {"mesh_term": "Coronavirus Infections"}, "intervention_browse": {"mesh_term": ["Ritonavir", "Lopinavir", "Hydroxychloroquine"]}, "patient_data": {"sharing_ipd": "No"}}}